Revenue of $18.7 million, a 66% increase over the same period last year

Gross margin of 82.2%, an increase of 340 basis points from the same period last year

Completed initial public offering with $107.1 million in proceeds, net of underwriting discounts, commissions and offering costs

Interim results from ALIGN3D™ clinical study demonstrating positive radiographic and patient-reported outcomes starting at 6 weeks and maintained at 12 months